905818-69-1

Basic information

• Product Name: Bupropion HydrobroMide
• Synonyms: Bupropion HydrobroMide
• CAS NO: 905818-69-1
• Molecular Formula: BrH*C₁₃H₁₈ClNO
• Molecular Weight: 320.65306
• Mol File: 905818-69-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 334.8°C at 760 mmHg
• Flash Point: 156.3°C
• Appearance: /
• Vapor Pressure: 0.000125mmHg at 25°C
• CAS DataBase Reference: Bupropion HydrobroMide(CAS DataBase Reference)
• NIST Chemistry Reference: Bupropion HydrobroMide(905818-69-1)
• EPA Substance Registry System: Bupropion HydrobroMide(905818-69-1)

Safety Data

• Hazardous Substances Data: 905818-69-1(Hazardous Substances Data)

Usage

General Description

Bupropion hydrobromide is a medication that is used to treat depression and seasonal affective disorder. It belongs to a class of drugs called atypical antidepressants, and it works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine. This helps to improve mood and reduce the symptoms of depression. Bupropion hydrobromide is available in extended-release tablet form and is usually taken once or twice a day. It should be taken exactly as prescribed by a doctor, and patients should not stop taking it without consulting a healthcare professional, as suddenly stopping the medication can lead to withdrawal symptoms. Common side effects of bupropion hydrobromide include dry mouth, nausea, headache, and insomnia.

InChI:InChI=1/C13H18ClNO.BrH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

Upstream product

• 34841-39-9 bupropion 
• 31677-93-7 BUPROPION HYDROCHLORIDE 

Relevant articles and documents

Persistency of a two-fold embrace in crystalline phases of bupropion hydrohalides: A thorough ab initio x-ray powder diffraction study

Bupropion hydrohalide salts yield ten different crystal phases of bupropion (four hydrochloride, two hydrobromide, and four hydroiodide salts). Of these forms, only four have been previously characterized by single crystal or powder diffraction analysis. The structures of the six new crystal forms have been solved using state-of-the art structural powder diffraction methods. All ten phases have been found to be made up of the same supramolecular synthon packed in different ways. The supramolecular synthon common to all phases is a bupropion hydrohalide dimer held together by hydrogen bonding. The true driving force of the polymorphism of bupropion hydrohalides is therefore the ability of the bupropion hydrohalide dimer to pack in several different ways and not the ability of the molecule to form different hydrogen bonding motifs or to exist with aliphatic branches in different stable conformations.

MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.